Short answer
Perspective Therapeutics, Inc. (CATX) filed an 8-K current report with the SEC on November 6, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Updated interim Phase 1/2a results for VMT01 melanoma diagnosis and treatment presented at SITC’s 41st Annual Meeting.
Perspective Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Updated interim Phase 1/2a results for VMT01 melanoma diagnosis and treatment presented at SITC’s 41st Annual Meeting
- Trial targets unresectable or metastatic melanoma patients with melanocortin 1 receptor tumor expression
- Results may inform VMT01’s clinical proof-of-concept and development path, but remain interim early-stage data
- Press release and poster presentation provide the substantive efficacy and safety details in Exhibits 99.1 and 99.2
Item EX-99.1 · Exhibit EX-99.1
- Phase 1/2a VMT01 melanoma data: 75% disease control at the 3.0 mCi focus dose
- Two of eight patients achieved partial responses, with one ongoing approximately 40 weeks after first treatment
- Safety profile favorable across 20 patients: no dose-limiting toxicities, treatment-related serious adverse events, or discontinuations
- Grade 3 or higher adverse events in five patients, 25%, none treatment-related
- Continued dose optimization supports further development, but efficacy remains interim and based on a small cohort
Item EX-99.2 · Exhibit EX-99.2
- Phase I/IIa monotherapy data support continued development of [212Pb]VMT01 in previously treated metastatic melanoma
- No dose-limiting toxicities among 20 patients, with grade ≥3 and serious TEAEs each affecting 5 participants (25%)
- Objective response rate 10%, including 2 confirmed partial responses, both in the 3 mCi cohort
- 3 mCi cohort showed 75% disease control, with 2 additional patients achieving durable stable disease
- Combination cohorts with nivolumab remain under evaluation, while expansion depends on recommended phase 2 dose selection
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Perspective Therapeutics, Inc. 8-K filings
Get the next CATX 8-K as it lands
Follow CATX for push alerts, or ask the research agent what this filing means.